Report
Novo agrees to pay up to $2.6 billion to license Hengrui Pharma’s experimental weekly weight-loss pill
STAT reports the agreement is for a pill from China’s Hengrui Pharma that remains experimental.
TLDR
STAT reports Novo has agreed to pay up to $2.6 billion to license an experimental weekly weight-loss pill from China’s Hengrui Pharma.
Combined views
2.3K
1 Source, first seen ago
likes